ArticleArchives of microbiology2026
Anti-biofilm and anti-virulence activity of a rare actinobacteria Nocardia sp. EMB45 against Pseudomonas aeruginosa.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa forms resilient, antibiotic-tolerant biofilms, with quorum sensing (QS) as a central regulator of biofilm formation and virulence. In this study, we report Nocardia sp. EMB45, isolated from termite nest soil, as a novel source of antibiofilm metabolites. The crude extract inhibited P. aeruginosa PAO1 biofilm formation with a minimum biofilm inhibitory concentration (MBIC) of 6 mg/mL. Morphological analyses by FE-SEM and AFM revealed disrupted biofilm architecture, while confocal microscopy showed sparse and less dense biofilms composed predominantly of viable cells. Mechanistic studies demonstrated QS inhibition using the biosensor Chromobacterium violaceum CV026, suggesting interference with AHL-mediated signalling. The extract markedly reduced QS-regulated phenotypes, including exopolysaccharide production and virulence factors. qRT-PCR analysis demonstrated strong suppression of QS genes, with lasI, lasR, rhlI, and rhlR showing ~ 14- to 20-fold downregulation relative to untreated controls. GC–MS analysis identified 22 metabolites, among which compound C1 (1,2-oxathiane,6-dodecyl-,2,2-dioxide) and compound C4 (Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)-) exhibited the highest binding affinities toward LasR and RhlR, respectively, in molecular docking and dynamics simulations. These findings highlight Nocardia sp. EMB45 is a promising and underexplored source of antibiofilm metabolites with potential applications in anti-virulence therapy against P. aeruginosa.
Indexed as
Identifiers
41563494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.